Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
Cancer Treat Rev. 2021 Nov;100:102281. doi: 10.1016/j.ctrv.2021.102281. Epub 2021 Aug 18.
In the last decades several anti-cancer drugs have been developed to treat patients with breast cancer, many of them orally administered, with ongoing efforts to substitute parenteral drugs with oral therapy. The latter is attractive because of its convenience and ease of administration, finally improving quality of life. The drawback of oral administration is that exposure to the drug is affected by different factors and the high variability, combined with the relatively narrow therapeutic index of most of these agents, would predispose some individuals to risk for treatment inefficacy or increase toxicity. Among these factors, food plays a central role since it can influence the pharmacokinetic profile of several drugs. Consequently, health care providers and patients should be aware of possible interaction to optimize treatment. In this review a systematic evaluation of package inserts and literature have been performed to analyse the effect of fed or fasted state on pharmacokinetic of all oral drugs currently approved for breast cancer, offering clear recommendations for their use daily practice.
在过去的几十年中，已经开发出了几种抗癌药物来治疗乳腺癌患者，其中许多是口服药物，并且正在努力用口服疗法替代注射药物。口服疗法具有便利性和易用性，最终可以提高生活质量，这是其吸引人的地方。然而，口服给药的缺点是药物暴露会受到多种因素的影响，并且大多数这些药物的变异性较高，再加上相对较窄的治疗指数，这可能会使某些人面临治疗无效或毒性增加的风险。在这些因素中，食物起着核心作用，因为它会影响几种药物的药代动力学特征。因此，医护人员和患者应该意识到可能的相互作用，以优化治疗。在本综述中，对包装说明书和文献进行了系统评估，以分析目前批准用于乳腺癌的所有口服药物在进食或禁食状态下对药代动力学的影响，为其在日常实践中的使用提供了明确的建议。
